AAM Issue Brief: Inter Partes Review (IPR) | Association for Accessible Medicines
GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!

AAM Issue Brief: Inter Partes Review (IPR)

Inter Partes Review (IPR) Is Necessary to Lower Drug Prices by Ensuring that PTO Only Grants Patents that Reflect True Innovation

The problem remains: patients are paying too much for brand-name drugs. 

Generic and biosimilar medicines are a proven solution to high drug prices and policies that continue to foster generic access are needed. Maintaining a strong and efficient IPR process is just one of those policies. 

View Brief

 

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.